Crossject

Equities

ALCJ

FR0011716265

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 11:16:10 2024-05-10 am EDT			5-day change	1st Jan Change
2.12 ^EUR	+0.47%		-4.93%	-57.34%

May. 03	Crossject: praised for extended agreement on Zepizure	CF
May. 02	Crossject Signs A Geographic Extension of ZEPIZURE Commercialization Agreement in Europe	CI

Crossject Société Anonyme announced that it has received €1.1 million in funding from Bpifrance Investissement and another investor

February 03, 2019

Crossject Société Anonyme (ENXTPA:ALCJ) announced that it has received funding for gross proceeds of €1.1 million on February 4, 2019. The company issued loan in the transaction. The transaction included participation from Bpifrance Investissement and the Bourgogne Franche Comté region. The loan carries a zero coupon rate.

Latest news about Crossject

Crossject: praised for extended agreement on Zepizure	May. 03	CF
Crossject Signs A Geographic Extension of ZEPIZURE Commercialization Agreement in Europe	May. 02	CI
CROSSJECT : We welcome the securing of the group’s financial needs	May. 02	AL
CROSSJECT : Patience is a virtue… hopefully	Apr. 03	AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
CROSSJECT : Invest Securities slightly reduces its target	Feb. 28	CF
CROSSJECT : Securing the financing needs	Feb. 28	AL
Crossject: share price falls after convertible bond issue	Feb. 27	CF
Crossject Société Anonyme announced that it expects to receive ?12 million in funding	Feb. 25	CI
CROSSJECT : No news is not always good news...	Feb. 08	AL
Crossject: strategy advances, but visibility worries	Feb. 07	CF
CROSSJECT : Marketing initiative in the US	Jan. 06	AL
Crossject: Syneos Health hired for Zepizure in the USA	Jan. 05	CF
French Pharmaceutical Crossject Taps Syneos Health for US Commercialization of Epilepsy Rescue Treatment	Jan. 05	MT
CROSSJECT : A new distribution agreement in Northern Europe	Jan. 03	AL
France's Crossject Inks New Commercialization Deal for Epileptic Seizure Therapy in Northern EU	Dec. 22	MT
Crossject: commercial agreement in Northern Europe	Dec. 22	CF
Crossject Signs ZENEO(R) Commercialization Agreement for Northern Europe	Dec. 22	CI
CROSSJECT : H1 23: no surprises before the release of the detailed accounts in October	23-09-28	AL
Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Crossject: improved ESG rating in the Gaïa ranking	23-09-11	CF
Crossject: manufacturing audits passed	23-09-05	CF
Crossject Completes European, US Audits for Manufacturing of Seizure Medication for US	23-09-05	MT
AFT Pharmaceuticals Secures Australia, New Zealand License for Epilepsy Rescue Medication	23-07-20	MT
Crossject Société Anonyme Signs New Licensing Agreement on Zeno Midazolam Epilepsy Rescue Therapy with AFT Pharmaceuticals for Australia & New Zealand	23-07-20	CI

Chart Crossject

Duration

Period

More charts

Company Profile

Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.

Sector

Medical Equipment, Supplies & Distribution

More about the company